Essential Thrombocythemia, Idiopathic Myelofibrosis, Myelofibrosis, Polycythemia Vera
Conditions
Keywords
Myeloproliferative Disease, Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
Brief summary
This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues: * Peripheral blood * Bone marrow * Bone marrow biopsy * A phlebotomized unit of blood * Spleen cells * Toenail clippings This material will be used for the study of Myeloproliferative Disorders (MPD) by researchers. The goals of this research study are to understand the causes of MPDs, how to diagnose them more easily and how to treat them better. MPD is a disease affecting hematopoietic stem cells. Hematopoietic stem cells are cells that make blood cells. These stem cells grow in the center portion of the bones called bone marrow. Under some conditions, these cells are also found in blood. There are several diseases, which are classified as MPD. These include polycythemia vera (too many red blood cells), essential thrombocythemia (too many platelets), and idiopathic myelofibrosis (abnormal blood cells and fibers build up in the bone marrow). These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments.
Interventions
None listed
Sponsors
Myeloproliferative Disorders-Research Consortium
National Cancer Institute (NCI)
Icahn School of Medicine at Mount Sinai
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) are eligible. * Newly diagnose MPD patients as well as previously treated for a MPD are eligible. * Signed informed consent is required from each patient at the time of enrollment.
Exclusion criteria
* Patients currently participating in experimental treatment arms of MPD-RC protocols, or other experimental treatment protocols are not eligible during the period they are on study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To collect and store tissue specimens from patients with MPDs including PV, IM, ET. The samples will be used to conduct laboratory investigations to help define mechanisms involved in the pathophysiology and treatment of these disorders. | 3 years |
Countries
Italy, United States
Outcome results
None listed